Effect of the thyroid transcription factor 1 expression and treatment discontinuation due to adverse events on progression-free survival in patients with advanced non-squamous non-small cell lung cancer treated with pembrolizumab plus pemetrexed and platinum chemotherapy: a Japanese four-hospital, retrospective study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Thyroid transcription factor 1 (TTF-1) expression may predict treatment response in non-squamous non-small cell lung cancer (NS-NSCLC) patients receiving chemotherapy. TTF-1 positivity showed a trend towards longer progression-free survival (PFS).
Area Of Science
- Oncology
- Molecular Biology
- Clinical Research
Background
- Thyroid transcription factor 1 (TTF-1) expression is linked to improved outcomes in non-squamous non-small cell lung cancer (NS-NSCLC) treated with immune checkpoint inhibitors.
- The association between TTF-1 expression and adverse events (AEs) during combination chemotherapy remains unclear.
Purpose Of The Study
- To investigate the impact of TTF-1 expression and AEs on progression-free survival (PFS) in NS-NSCLC patients treated with pembrolizumab plus pemetrexed and platinum chemotherapy.
- To determine if TTF-1 can predict treatment response and prognosis in this patient group.
Main Methods
- Retrospective study of 79 NS-NSCLC patients treated between 2018 and 2022.
- Analysis of TTF-1 expression, AEs, and PFS using proportional hazards analysis.
Main Results
- A trend towards longer PFS was observed in TTF-1 positive patients (P=0.190).
- Treatment interruption due to AEs significantly extended PFS (HR=0.32, P=0.005).
- Pembrolizumab plus pemetrexed and platinum chemotherapy for TTF-1 positive NS-NSCLC showed significantly longer PFS after AE-related discontinuation (827 vs. 210 days, P=0.021).
Conclusions
- TTF-1 measurement may predict treatment response to pembrolizumab plus pemetrexed and platinum chemotherapy in NS-NSCLC.
- TTF-1 may also serve as a prognostic marker when treatment is discontinued due to AEs.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
